4,4'-Diaminodiphenylsulfone CAS#80-08-0
Powerful Anti-Leprosy Activity – Exhibits strong antibacterial effects against Mycobacterium leprae and is the first-line drug for leprosy treatment.
Dual Antibacterial & Anti-Inflammatory Action – Inhibits bacterial folic acid synthesis while reducing inflammation and oxidative free-radical damage.
High Therapeutic Efficiency – Oral administration achieves blood concentrations hundreds of times higher than the minimum inhibitory concentration required.
Broad Clinical Applications – Effective in treating infectious diseases, inflammatory skin conditions, autoimmune bullous disorders, and urticaria.
Products Description of 4,4'-Diaminodiphenylsulfone CAS#80-08-0
Dapsone is a sulfone-class antibacterial agent with strong activity against Mycobacterium leprae and has been extensively used in the treatment of leprosy. As the first-line drug for leprosy therapy, it inhibits bacterial dihydrofolate synthase (DHPs), disrupts folic acid synthesis, and thereby interferes with bacterial protein production. In addition to its antibacterial action, dapsone exhibits notable anti-inflammatory effects, effectively scavenging toxic oxygen free radicals and other reactive substances generated following neutrophil stimulation. It also suppresses neutrophil aggregation and activation, reduces the release of inflammatory mediators, and consequently limits tissue damage. Studies indicate that an oral dose of 100 mg of dapsone achieves blood concentrations 500–600 times higher than the minimum inhibitory concentration required to suppress Mycobacterium leprae. Recent research further shows that dapsone is applicable in the treatment of various infectious diseases, inflammatory dermatoses, autoimmune bullous disorders, urticaria, and other conditions, demonstrating a broad range of clinical indications.
4,4'-Diaminodiphenylsulfone Chemical Properties
| Melting point | 175-177 °C(lit.) |
| Boiling point | 511.7±35.0 °C(Predicted) |
| density | 1.2701 (rough estimate) |
| vapor pressure | 0.004Pa at 25℃ |
| refractive index | 1.5950 (estimate) |
| storage temp. | 2-8°C |
| solubility | 0.38g/l |
| form | Crystalline Powder |
| pka | pKb 13.0(at 25℃) |
| color | White to beige |
| PH | 5.5-7.5 (H2O, 20℃)(saturated aqueous solution) |
| Water Solubility | <0.1 g/100 mL at 20 ºC |
| Merck | 142,822 |
| BRN | 788055 |
| BCS Class | 4,2 |
| Stability: | Stable. Combustible. Incompatible with strong oxidizing agents. |
| InChIKey | MQJKPEGWNLWLTK-UHFFFAOYSA-N |
| LogP | 0.97 at 25℃ |
| CAS DataBase Reference | 80-08-0(CAS DataBase Reference) |
| NIST Chemistry Reference | Dapsone(80-08-0) |
| IARC | 3 (Vol. 24, Sup 7) 1987 |
| EPA Substance Registry System | Dapsone (80-08-0) |
Safety Information
| Hazard Codes | Xn |
| Risk Statements | 22 |
| Safety Statements | 22 |
| RIDADR | 3249 |
| WGK Germany | 1 |
| RTECS | BY8925000 |
| TSCA | Yes |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29051620 |
| HS Code | 29309070 |
| Hazardous Substances Data | 80-08-0(Hazardous Substances Data) |
| Toxicity | LD50 orally in Rabbit: 1000 mg/kg LD50 dermal Rabbit > 4000 mg/kg |




